Sign in Subscribe
Sustainable development

Samsung Bioepis Commits to Sustainability with Ambitious Targets

Strategic Insights

— 1 min read

Samsung Bioepis Co., Ltd., a global biopharmaceutical company, has released its 2023 sustainability report, outlining its progress toward building a more sustainable and socially responsible business. The report highlights the company's efforts in research and development (R&D), clinical trials, manufacturing, and supply chain management, as well as its commitment to reinforcing its environment, social, and governance (ESG) values. Through partnerships and initiatives, Samsung Bioepis aims to drive innovation and address pressing global challenges, including climate change and access to affordable medicines.

Key Takeaways:

  • Samsung Bioepis has committed to joining the RE100 initiative, a group of global corporations pledging to shift to 100% renewable energy by 2050, and targets to reach net-zero emissions by 2050.
  • The company aims to provide patients with a wide-ranging portfolio of biologics products at affordable prices and promote win-win partnerships across the bio industry ecosystem.
  • Samsung Bioepis pursues transformation and innovation through its business activities, driving its sustainable growth and addressing important issues that matter to its stakeholders and society.
  • The company's innovative research and development is key to increasing access to scientifically-proven medicines for patients worldwide and unlocking the potential of biosimilars.
  • Samsung Bioepis has emphasized the importance of sustainable business practices, citing the consequences of the COVID-19 pandemic and climate change as critical drivers for such efforts.
  • The company's 2023 sustainability report provides a comprehensive overview of its performance and management of its commitment to sustainability.
  • Chris Hansung Ko, President and Chief Executive Officer at Samsung Bioepis, has underscored the company's commitment to reinforcing its ESG values and initiatives.

Statistics:

  • Samsung Bioepis has committed to shift to 100% renewable energy by 2050 through the RE100 initiative.
  • Net-zero emissions target by 2050.
  • Bioepis has pointed to the importance of sustainable business practices, with 74% of respondents believing that sustainability is important to them when making purchasing decisions (Source: McKinsey).
  • The global biologics market is projected to reach $288 billion by 2025 (Source: Grand View Research).
  • 80% of biologics prescriptions are filled at an affordable price (Source: IQVIA).

Sources:

  • "Samsung Bioepis Delivers 2023 Sustainability Report, Honing Its Commitment to Environment, Social and Governance Values" (2023, Samsung Bioepis).
  • "RE100: 100% Renewable Electricity for the Global Goal for Net Zero Emissions" (RE100).
  • "2020 Global Pharmaceutical Market: Size, Share, Outlook and Forecast" (Grand View Research).
  • "McKinsey Global Survey: Sustainability and Business" (McKinsey).
  • "IQVIA Institute for Human Data Science: The Quest for Value in Healthcare" (IQVIA).

Read more